J&J CFO on Q1 earnings beat, Covid vaccine pause in U.S.

Johnson & Johnson on Tuesday reported $100 million in first-quarter sales of its Covid-19 vaccine that’s on hold in the U.S. while U.S. health regulators investigate a rare blood-clotting issue. Johnson & Johnson CFO Joseph Wolk joined CNBC's Meg Tirrell to discuss the results as well as U.S. health officials' decision to recommend states pause the distribution of the vaccine due to those health concerns.